R 0006/25 (Petition for review) of 12.09.2025
- European Case Law Identifier
- ECLI:EP:BA:2025:R000625.20250912
- Date of decision
- 12 September 2025
- Case number
- R 0006/25
- Petition for review of
- -
- Application number
- 15177140.9
- Language of proceedings
- English
- Distribution
- No distribution (D)
- Download
- Decision in English
- OJ versions
- No OJ links found
- Other decisions for this case
- -
- Abstracts for this decision
- -
- Application title
- (+)-2-[1-(3-ETHOXY-4-METHOXYPHENYL)-2-METHYLSULFONYLETHYL]-4-ACETYLAMINOISOINDOLINE-1,3-DIONE: METHODS OF USING AND COMPOSITIONS THEREOF
- Applicant name
- Amgen (Europe) GmbH
- Opponent name
- Teva Pharmaceutical Industries Ltd.
Hoffmann Eitle Patent- und Rechtsanwälte
Partnerschaftsgesellschaft mbB
Accord Healthcare Ltd
ZAKLADY FARMACEUTYCZNE POLPHARMA S.A.
Generics (UK) Ltd
Sanovel Ilaç Sanayi Ve Ticaret Anonim Sirketi
Hexal AG
Química Sintética, S.A.
Cipla Ltd
Zentiva k.s.
KRKA, d.d., Novo mesto
Dr. Reddy's Laboratories Limited
Alfred E. Tiefenbacher (GmbH & Co. KG)
STADA Arzneimittel AG
Galenicum Health S.L.U. - Board
- -
- Headnote
- -
- Relevant legal provisions
- European Patent Convention Art 112a(2)(c)European Patent Convention Art 113European Patent Convention R 106European Patent Convention R 109(2)(a)
- Keywords
- Petition for review - clearly inadmissible or unallowable
Petition for review - fundamental violation of Art. 113 EPC (no) - Catchword
- -
- Cited cases
- R 0016/13T 0002/83T 0249/88T 0149/93T 1053/93T 0318/02T 1877/08T 2168/11T 0867/13T 3103/19
- Citing cases
- -
Order
For these reasons it is decided that:
The petition for review is unanimously rejected as being
clearly inadmissible or unallowable.